2025 -  WEEK 10 - What's New in RWE Research

 

  1. A Pharmacovigilance Analysis of Post-Marketing Safety of Tezepelumab. Li H, Wang C, Guo C. J Allergy Clin Immunol Pract. 2025 Mar;13(3):551-558.e6. doi: 10.1016/j.jaip.2024.10.045. Epub 2024 Nov 7. PMID: 39521341

 

  1. The relevance of the real-world evidence in research, clinical, and regulatory decision making. Costa V, Custodio MG, Gefen E, Fregni F. Front Public Health. 2025 Feb 18;13:1512429.

 

  1. Trend and Provider- and Organizational-Level Factors Associated With Early Palliative Care Billing Among Patients Diagnosed With Distant-Stage Cancers in 2010-2019 in the United States. Hu X, Kwon Y, Jiang C, Fan Q, Shi KS, Zheng ZJ, Zhao J, Warren JL, Yabroff KR, Han X.J Clin Oncol. 2025 Mar 7:JCO2401935.

 

  1. Augmenting Insufficiently Accruing Oncology Clinical Trials Using Generative Models: Validation Study. El Kababji S, Mitsakakis N, Jonker E, Beltran-Bless AA, Pond G, Vandermeer L, Radhakrishnan D, Mosquera L, Paterson A, Shepherd L, Chen B, Barlow W, Gralow J, Savard MF, Fesl C, Hlauschek D, Balic M, Rinnerthaler G, Greil R, Gnant M, Clemons M, El Emam K.J Med Internet Res. 2025 Mar 5;27:e66821.

 

  1. Empowering Health Care Actors to Contribute to the Implementation of Health Data Integration Platforms: Retrospective of the medEmotion Project. Parciak M, Pierlet N, Peeters LM. J Med Internet Res. 2025 Mar 4;27:e68083.

 

  1. Hypertension associated with serotonin reuptake inhibitors: A new analysis in the WHO pharmacovigilance database and examination of dose-dependency. Chrétien B, Rabiaza A, Kazuki N, Fedrizzi S, Sassier M, Dolladille C, Alexandre J, Humbert X. PLoS One. 2025 Mar 7;20(3):e0317841.

 

  1. Real world data on dual BLyS/APRIL inhibition with telitacicept for lupus nephritis. Jin J, Tan M, Tan Y, Zhao M. Nephrol Dial Transplant. 2025 Mar 6:gfaf049.

 

  1. Expert opinion on the integration of combination therapy into the treatment algorithm for the management of dyslipidaemia. Parhofer KG, Aguiar C, Banach M, Drexel H, Gouni-Berthold I, de Isla LP, Rietzschel E, Zambon A, Ray KK.Eur Heart J Cardiovasc Pharmacother. 2025 Mar 6:pvaf007.

 

  1. Real-world evidence: state-of-the-art and future perspectives. Fitzke H, Fayzan T, Watkins J, Galimov E, Pierce BF.J Comp Eff Res. 2025 Mar 7:e240130.

 

  1. Safety and efficacy of human umbilical cord-derived mesenchymal stem cells in COVID-19 patients: A real-world observation. Wang S, Yang T, Li T, Shi L, Xu R, Zhang C, Wang Z, Zhang Z, Shi M, Xu Z, Wang FS.Chin Med J (Engl). 2025 Mar 7.

 

  1. Goserelin 3-month depot shows non-inferiority to the monthly formulation in U.S. patients with premenopausal breast cancer: a real-worldevidence McCann KE, Osman N, Cannon J, Brent L, Wang Y, Tepsick J, Mandora PV, Miller V, Martin N, Kaklamani VG.Breast Cancer Res Treat. 2025 Mar 6.

 

  1. A Brief Report on a Systematic Review of Real-World Effectiveness Studies of ICS/LAMA/LABA for Treatment of Adults with Asthma in the US. Noorduyn SG, Begaj K, Martin A, Forero-Schwanhaeuser S, Schaible K, Moore A, Paczkowski R.Pulm Ther. 2025 Mar 6.

 

  1. Tirzepatide and major adverse limb events: Insights from a multicenter real-world analysis in PAD and diabetes patients. Wu JY, Tu WL, Yu T, Liao KM, Lin YM.Diabetes Res Clin Pract. 2025 Mar 4:112083.

 

  1. Aggressive Ablation versus Regular Ablation for Persistent Atrial Fibrillation: A Multicenter Real-World Cohort Study. Li K, Shi Y, Wang X, Ye P, Han B, Jiang W, Zhang Y, Zheng Q, Ji A, Zhang M, Wang Y, Wu S, Xu K, Qin M, Liu X, Hou X. 2025 Mar 6:euaf045.

 

  1. Mirikizumab in the Treatment of Ulcerative Colitis: Initial Real-World Data in a Population from a Large Tertiary Center. St-Pierre J, Choi D, Fear E, Choi NK, Mathew AJ, Cohen RD, Dalal SR, Pekow J, Krugliak Cleveland N, Rubin DT.Dig Dis Sci. 2025 Mar 6.

 

  1. PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis. Beaudart C, Veronese N, Douxfils J, Thiyagarajan JA, Bolzetta F, Albanese P, Voltan G, Alokail M, Harvey NC, Fuggle NR, Rizzoli R, Reginster JY.Osteoporos Int. 2025 Mar 6.

 

  1. Characterizing Treatment Effect Heterogeneity Using Real-World Data. Thelen H, Hennessy S.Clin Pharmacol Ther. 2025 Mar 6.

 

  1. SLCO1B1 Functional Variants, Bilirubin, Statin-Induced Myotoxicity, and Recent Sub-Saharan African Ancestry: A Precision Medicine Health Equity Study. Haldar T, Kvale M, Yang J, Douglas MP, Coyote-Maetas W, Kachuri L, Witte JS, Iribarren C, Medina MW, Krauss RM, Yee SW, Oni-Orisan A.Clin Pharmacol Ther. 2025 Mar 6.

 

  1. Switching from intravenous to oral antibiotic therapy in the treatment of infective endocarditis: a case series and literature review of real-world data. Lundgren LB, Albertini L, De Bona A, Tincati C, Augello M, Marchetti G.JAC Antimicrob Resist. 2025 Mar 4;7(2):dlaf032.

 

  1. Comparison of isatuximab-pomalidomide-dexamethasone versus elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data. Martino EA, Pitino A, Offidani M, Pepa RD, Gozzetti A, Bongarzoni V, Maroccia A, Amico V, Stefanoni P, Zamagni E, Terlizzi S, Derudas D, Palmieri S, Bianco R, Conticello C, Brunori M, Rago A, Lotti F, Fontana R, Sgherza N, Rossi E, Cafro AM, Febbo MA, Quinto AM, Cerchione C, Casaluci GM, Citro A, Califano C, Zambello R, Mangiacavalli S, Liberatore C, Buda G, De Magistris C, Amendola A, Vigna E, Bruzzese A, Barbieri E, Quaresima M, Roccotelli D, Farina F, Micozzi J, Vincelli ID, Tarantini G, Antonioli E, Aquino S, Maggi A, Lombardo A, Bertuglia G, Furlan A, Mele A, Annibali O, Cotzia E, Benvenuti P, De Paoli L, Barilà G, Morè S, De Stefano V, Di Raimondo F, Petrucci MT, Bolli N, Musto P, Neri A, Morabito F, Tripepi G, Gentile M. 2025 Mar 6.

 

  1. Effectiveness and safety of daily oral semaglutide in people with type 2 diabetes mellitus switching from sulfonylureas: A real-world retrospective study. Costa S, Miranda C, Elefante A, Vallone V, Vinci C, Borroni F, Brandoni G, Labate AM, Lo Pomo F, Strazzabosco M. Diabetes Obes Metab. 2025 Mar 6.

 

  1. Multicentre, real-world data of next-generation computer-assisted vacuum aspiration thrombectomy in acute pulmonary embolism. Sławek-Szmyt S, Stępniewski J, Kurzyna M, Klaudel J, Kuliczkowski W, Lewandowski M, Grabka M, Roik M, Ordiene R, Jankiewicz S, Kopeć G, Darocha S, Mroczek E, Widecka K, Kurzyna P, Lesiak M, Pruszczyk P, Araszkiewicz A.Respir Res. 2025 Mar 5;26(1):87.

 

  1. Real-World Evidence of Tralokinumab Effectiveness and Safety: A Systematic Review and Meta-analysis. Rønnstad ATM, Bunick CG, Chovatiya R, Kamata M, Nielsen ML, Isufi D, Thomsen SF, Vestergaard C, Wollenberg A, Egeberg A, Thyssen JP, Loft N. Am J Clin Dermatol. 2025 Mar 5.

 

  1. Effectiveness of nirsevimab in reducing hospitalizations in emergency departments due to bronchiolitis among infants under 3 months: a retrospective study. Marouk A, Verrat B, Pontais I, Cojocaru D, Chappuy H, Craiu I, Quagliaro P, Gajdos V, Soussan-Banini V, Gallien Y, Feral-Pierssens AL.Eur J Pediatr. 2025 Mar 5;184(3):229.

 

  1. Capturing breast cancer subtypes in cancer registries: insights into real-world incidence and survival. Vaz-Gonçalves L, Marquart-Wilson L, Protani MM, Stephensen MT, Moore J, Morris MF, Saunus JM, Reeves MM.J Cancer Policy. 2025 Mar 3:100567.

 

  1. What can real-world data teach us about treating patients with unresectable hepatocellular carcinoma? Dalbeni A, Cattazzo F, Natola LA, Zoncapè M, Faccincani D, Stefanini B, Ravaioli F, Villani R, Auriemma A, Sacerdoti D. Expert Rev Gastroenterol Hepatol. 2025 Mar 5.

 

  1. Evolution of the population with chronic kidney disease in Spain in the context of the COVID-19 pandemic: a longitudinal retrospective study. Bilbie-Lupchian L, Oliván-Blázquez B, González-Álvarez B, Matovelle-Ochoa P, Casado-Vicente V, Sánchez-Calavera MA.Prim Health Care Res Dev. 2025 Mar 5;26:e26.

 

  1. Treatment Patterns, Healthcare Resource Utilization, and Costs Among Patients Diagnosed With Locally Advanced/Metastatic Urothelial Carcinoma Prior to Receiving Enfortumab Vedotin: A Real-World Evidence Morgans AK, Mucha L, Quicquaro C, Shih V, Xie B, Young C, Yang H, Liu Q, Greatsinger A, Lax A.Int J Urol. 2025 Mar 5. doi: 10.1111/iju.70023. Online ahead of print.PMID: 40040557

 

  1. Hospital medical device quality and safety monitoring using real-world data from friuli venezia giulia regional health coordination agency. Flamigni A, Trojniak MP, Distefano L, Mattioni L, Cupo D, Zanier M, Arbo A. Expert Rev Med Devices. 2025 Mar 4.

 

  1. Effectiveness and Safety of Upadacitinib Induction Therapy for 223 Patients With Crohn's Disease: A GETAID Multicentre Cohort Study. Richard N, Amiot A, Seksik P, Altwegg R, Laharie D, Vuitton L, Nachury M, Bouguen G, Nancey S, Gilletta C, Rouilon C, Coffin B, Allez M, Buisson A, Le Berre C, Uzzan M, Caillo L, Pelletier AL, Peyrin-Biroulet L, Fumery M; GETAID. Aliment Pharmacol Ther. 2025 Mar 4.

 

  1. Mono and combination therapies in pulmonary arterial hypertension patients with comorbidities: A COMPERA analysis. Skowasch D, Pausch C, Huscher D, Pittrow D, Wede J, Kreimendahl F, Rosenkranz S, Beckmann S, Held M, Grünig E, Ghofrani HA, Klose H, Skride A, Halank M, Stadler S, Delcroix M, Vonk-Noordegraaf A, Ewert R, Kopec G, Hoeper MM, Olsson KM.ESC Heart Fail. 2025 Mar 4.

 

  1. Chronic Obstructive Pulmonary Disease Outcomes Among Individuals in Japan Who Switched to Heated Tobacco Products Compared to Those Who Continued Smoking or Formerly Smoked Combustible Cigarettes: Protocol for a Real-World Retrospective Study. Karcher H, Hibino M, Higashiue S, Boakye D, Chowdhury B, Picavet P, Haidar M, Lenart A. JMIR Res Protoc. 2025 Mar 4. doi: 10.2196/73436.

 

  1. Outcomes of Liposomal Irinotecan With 5-FU and Leucovorin in Patients With Metastatic Pancreatic Cancer and Borderline Performance Status. Chang CY, Chiu TJ, Chen YY, Chen JS, Chou WC. Cancer Diagn Progn. 2025 Mar 3;5(2):198-206.

 

  1. Statistical Methods for Baseline Adjustment and Cohort Analysis in Korean National Health Insurance Claims Data: A Review of PSM, IPTW, and Survival Analysis With Future Directions. Kim DW.J Korean Med Sci. 2025 Mar 3;40(8):e110.

 

  1. A state-of-the-art review of registries in spinal muscular atrophy: A valuable resource for clinical research. Balaji L, Farrar MA, Yiu EM, Kariyawasam D.J Neuromuscul Dis. 2025 Mar 3:22143602241313113.

 

  1. Lenvatinib in Relapsed/Metastatic Adenoid Cystic Carcinoma: Real-World Data From 17 Italian Centers. Caspani F, Cavalieri S, Orlandi E, Bergamini C, Resteghini C, Colombo E, Ottini A, Nuzzolese I, Alfieri S, Mirabile A, Cassano A, Bossi P, Ibrahim T, Cau MC, Ghiani M, Bertolini F, Ingargiola R, Fontana G, Licitra L, Locati LD. Head Neck. 2025 Mar 3.

 

  1. Trends in Readmissions Rates and Mortality after Cardiac Resynchronization Therapy in Patients with Nonischemic Cardiomyopathy. Sheth AR, Patel HP, Pandya K, Thakkar S, Prajapati K, Niar A, Labedi MR, DeSimone CV, Deshmukh A. Curr Cardiol Rev. 2025 Mar 3.

 

  1. Disproportionality Analysis and Causal Inference in Drug Safety. Scosyrev E, Behr S, Jain D, Ponnuru A, Michel C.Pharmaceut Med. 2025 Mar 4.

 

  1. The first real-world evidence on dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin followed by switch maintenance avelumab in advanced urothelial carcinoma: a propensity score-matched study. Taguchi S, Kawai T, Kurokawa Y, Saegusa N, Yamamoto M, Ambe Y, Honda K, Maki K, Fujii Y, Miyakawa J, Tokura Y, Inoue H, Kaneko T, Tanaka T, Nara K, Kamei J, Kakutani S, Yamada Y, Niimi A, Yamada D, Takada T, Nakagawa T, Kume H. Int J Clin Oncol. 2025 Mar 3.

 

  1. Real-world evidence is a vital tool for informing treatment strategies in chronic obstructive pulmonary disease. Feldman WB, Wang SV, Kesselheim AS. 2025 Mar 3;388:r427.

 

  1. A Unified Framework for Event-Based Frame Interpolation With Ad-Hoc Deblurring in the Wild. Sun L, Gehrig D, Sakaridis C, Gehrig M, Liang J, Sun P, Xu Z, Wang K, Van Gool L, Scaramuzza D. IEEE Trans Pattern Anal Mach Intell. 2025 Apr;47(4):2265-2279.

 

  1. IDHIRA: a prospective, observational study on ivosidenib in patients with IDH1R132-mutated advanced cholangiocarcinoma. Michl M, Hagemeyer N, Looß M, Grebhardt S, Ringwald K, Potthoff K.Future Oncol. 2025 Mar 3:1-8.

 

  1. Five-year trajectories of HbA1c by age, sex, ethnicity and deprivation in adults with newly diagnosed type 2 diabetes: Observational study in England. Bhattacharjee A, Ali MR, Kloecker D, Ling S, Balasubramanian GV, Gillies C, Davies M, Khunti K, Zaccardi F.Diabetes Obes Metab. 2025 Mar 3.

 

  1. Minimal Tofacitinib dose for Maintenance in Axial Spondyloarthritis: Real world data from a Resource-limited setting. Sreekanth A, George J, Ahmed S, Mehta P, Saijan S, Menon AR, Meghnathi B, Shenoy D P.Arthritis Rheumatol. 2025 Mar 3.

 

  1. Synthetic Data for the Get With The Guidelines-Stroke Registry. Wang L, Manchanda V, Picotte H, Beon C, Hall JL, Zhao J, Feng X.J Am Heart Assoc. 2025 Mar 4;14(5):e039667.

 

  1. Methodological challenges and clinical perspectives in evaluating new treatments for ultra rare cancers. Bellino S, La Salvia A.Curr Med Res Opin. 2025 Mar 4:1-5.

 

  1. Real-world dataof first-line treatment with pembrolizumab for NSCLC with high PD-L1 expression in elderly patients: a subgroup analysis of HOT/NJLCG2001. Tateishi K, Mizugaki H, Ikezawa Y, Morita R, Yokoo K, Sumi T, Aso M, Kikuchi H, Nakamura A, Sekikawa M, Yoshiike F, Kitamura Y, Kimura N, Hachiya T, Tsurumi K, Agatsuma T, Megumi F, Nakamura K, Jingu D, Yamamoto H, Kosaka M, Yokouchi H.Jpn J Clin Oncol. 2025 Mar 5;55(3):253-260.

 

  1. Public assistance and survival equality in patients with EGFR mutation-positive lung cancer. Uryu K, Imamura Y, Shimoyama R, Mase T, Fujimura Y, Hayashi M, Ohtaki M, Otani K, Hibino M, Horiuchi S, Fukui T, Fukai R, Chihara Y, Iwase A, Yamada N, Tamura Y, Harada H, Tsuya A, Okabe T, Fukuoka M, Minami H.Jpn J Clin Oncol. 2025 Mar 5;55(3):228-236.

 

  1. Effect of different durations of treatment with antihypertensive drugs with anticholinergic effects on the risk of dementia: a target trial emulation study. Aguado J, Gutierrez L, Forns J, Vila-Guilera J, Rothman KJ, García-Albéniz X. Am J Epidemiol. 2025 Mar 4;194(3):691-698.

 

  1. Mucosal and Transmural Healing and Long-term Outcomes in Crohn's Disease. Sands BE, Danese S, Chapman JC, Gurjar K, Grieve S, Thakur D, Griffith J, Joshi N, Kligys K, Dignass A.Inflamm Bowel Dis. 2025 Mar 3;31(3):857-877.